ID: ALA319493

Max Phase: Preclinical

Molecular Formula: C12H18N4O3S

Molecular Weight: 298.37

Molecule Type: Small molecule

Representations

Canonical SMILES:  NC(=O)[C@H]1CS[C@@H]2C[C@@H](NC(=O)[C@@H]3CCCN3)C(=O)N12

Standard InChI:  InChI=1S/C12H18N4O3S/c13-10(17)8-5-20-9-4-7(12(19)16(8)9)15-11(18)6-2-1-3-14-6/h6-9,14H,1-5H2,(H2,13,17)(H,15,18)/t6-,7+,8+,9+/m0/s1

Standard InChI Key:  NQEUVKZPCBSIAC-JQCXWYLXSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 298.37

Molecular Weight (Monoisotopic): 298.1100

AlogP: -1.62

#Rotatable Bonds: 3

Polar Surface Area: 104.53

Molecular Species: BASE

HBA: 5

HBD: 3

#RO5 Violations: 0

HBA (Lipinski): 7

HBD (Lipinski): 4

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 12.27

CX Basic pKa: 9.50

CX LogP: -1.81

CX LogD: -3.89

Aromatic Rings: 0

Heavy Atoms: 20

QED Weighted: 0.58

Np Likeness Score: -0.22

References

1. Khalil EM, Pradhan A, Ojala WH, Gleason WB, Mishra RK, Johnson RL..  (1999)  Synthesis and dopamine receptor modulating activity of substituted bicyclic thiazolidine lactam peptidomimetics of L-prolyl-L-leucyl-glycinamide.,  42  (15): [PMID:10425107] [10.1021/jm990140n]

2. Dolbeare K, Pontoriero GF, Gupta SK, Mishra RK, Johnson RL..  (2003)  Synthesis and dopamine receptor modulating activity of 3-substituted gamma-lactam peptidomimetics of L-prolyl-L-leucyl-glycinamide.,  46  (5): [PMID:12593653] [10.1021/jm020441o]

Source

Source(1):

• Scientific Literature